A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth

Oncotarget

Volumn 7, Issue 14, 2016, Pages 18295-18308

  Patel, Yogin ^a   Shah, Nirav ^a   Lee, Ji Shin ^b   Markoutsa, Eleni ^a   Jie, Chunfa ^c   Liu, Shou ^a   Botbyl, Rachel ^a   Reisman, David ^a   Xu, Peisheng ^a   Chen, Hexin ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Chonnam National University   (South Korea)

^c DES MOINES UNIVERSITY   (United States)

Author keywords

Breast cancer; HER2; MicroRNA; MiR 489; Tumor suppressor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICRORNA; MICRORNA 489; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; MIRN489 MICRORNA, HUMAN; PTPN11 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER CELL LINE; CANCER GROWTH; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTRACELLULAR SIGNALING; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); RNA ANALYSIS; RNA DYSREGULATION; RNA PROCESSING; TUMOR XENOGRAFT; ANIMAL; BREAST; BREAST TUMOR; CANCER TRANSPLANTATION; FEEDBACK SYSTEM; FLUORESCENCE IN SITU HYBRIDIZATION; HEK293 CELL LINE; MCF-7 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEEDBACK, PHYSIOLOGICAL; HEK293 CELLS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; MICE; MICE, NUDE; MICRORNAS; NEOPLASM TRANSPLANTATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; TRANSPLANTATION, HETEROLOGOUS;

EID: 84975478330     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7577     Document Type: Article

References (55)

1. Higgins MJ and Baselga J. Targeted therapies for breast cancer. J Clin Invest. 2011; 121:3797-3803
2. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:2724-2729
3. Shah NR and Chen H. MicroRNAs in pathogenesis of breast cancer:Implications in diagnosis and treatment. World journal of clinical oncology. 2014; 5:48-60
4. Gajria D and Chandarlapaty S. HER2-amplified breast cancer:mechanisms of trastuzumab resistance and novel targeted therapies. Expert review of anticancer therapy. 2011; 11:263-275
5. Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME and Jones FE. Oncogenic HER2(Delta)16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis. 2010; 31:2049-2057
6. Zhu X and Verma S. Targeted therapy in her2-positive metastatic breast cancer:a review of the literature. Current oncology. 2015; 22:S19-28
7. Corsini LR, Bronte G, Terrasi M, Amodeo V, Fanale D, Fiorentino E, Cicero G, Bazan V and Russo A. The role of microRNAs in cancer:diagnostic and prognostic biomarkers and targets of therapies. Expert opinion on therapeutic targets. 2012; 16:S103-109
8. Indira Chandran V, Eppenberger-Castori S, Venkatesh T, Vine KL and Ranson M. HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer. Oncoscience. 2015; 2:207-224. doi:10.18632/oncoscience.146
9. Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L and Yu H. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast cancer research and treatment. 2009; 117:131-140
10. Zhou J, Tian Y, Li J, Lu B, Sun M, Zou Y, Kong R, Luo Y, Shi Y, Wang K and Ji G. miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2. Biochem Biophys Res Commun. 2013; 433:207-212
11. Adachi R, Horiuchi S, Sakurazawa Y, Hasegawa T, Sato K and Sakamaki T. ErbB2 down-regulates microRNA-205 in breast cancer. Biochemical and biophysical research communications. 2011; 411:804-808
12. Wee EJ, Peters K, Nair SS, Hulf T, Stein S, Wagner S, Bailey P, Lee SY, Qu WJ, Brewster B, French JD, Dobrovic A, Francis GD, Clark SJ and Brown MA. Mapping the regulatory sequences controlling 93 breast cancer-associated miRNA genes leads to the identification of two functional promoters of the Hsa-mir-200b cluster, methylation of which is associated with metastasis or hormone receptor status in advanced breast cancer. Oncogene. 2012; 31:4182-4195
13. Wang SE and Lin RJ. MicroRNA and HER2-overexpressing Cancer. Microrna. 2013; 2:137-147
14. Talotta F, Cimmino A, Matarazzo MR, Casalino L, De Vita G, D'Esposito M, Di Lauro R and Verde P. An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation. Oncogene. 2009; 28:73-84
15. Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Menard S, Croce CM and Tagliabue E. microRNA-205 regulates HER3 in human breast cancer. Cancer Res. 2009; 69:2195-2200
16. Ichikawa T, Sato F, Terasawa K, Tsuchiya S, Toi M, Tsujimoto G and Shimizu K. Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells. PLoS One. 2012; 7:e31422
17. Cheung TH, Quach NL, Charville GW, Liu L, Park L, Edalati A, Yoo B, Hoang P and Rando TA. Maintenance of muscle stem-cell quiescence by microRNA-489. Nature. 2012; 482:524-528
18. Kikkawa N, Hanazawa T, Fujimura L, Nohata N, Suzuki H, Chazono H, Sakurai D, Horiguchi S, Okamoto Y and Seki N. miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). British journal of cancer. 2010; 103:877-884
19. Jiang L, He D, Yang D, Chen Z, Pan Q, Mao A, Cai Y, Li X, Xing H, Shi M, Chen Y, Bruce IC, Wang T, Jin L, Qi X, Hua D, et al. MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway. FEBS letters. 2014; 588:2009-2015
20. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI and Kovalchuk O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. International journal of cancer. 2010; 127:1785-1794
21. Pinatel EM, Orso F, Penna E, Cimino D, Elia AR, Circosta P, Dentelli P, Brizzi MF, Provero P and Taverna D. miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions. PLoS One. 2014; 9:e84859
22. Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK and Sartorius CA. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene. 2014; 0
23. Le MT, Hamar P, Guo C, Basar E, Perdigao-Henriques R, Balaj L and Lieberman J. miR-200-containing extracellular vesicles promote breast cancer cell metastasis. J Clin Invest. 2014; 124:5109-5128
24. Feliciano A, Castellvi J, Artero-Castro A, Leal JA, Romagosa C, Hernandez-Losa J, Peg V, Fabra A, Vidal F, Kondoh H, Ramon YCS and Lleonart ME. miR-125b Acts as a Tumor Suppressor in Breast Tumorigenesis via Its Novel Direct Targets ENPEP, CK2-alpha, CCNJ, and MEGF9. PLoS One. 2013; 8:e76247
25. Hu Y, Zhu Q and Tang L. MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression. PLoS One. 2014; 9:e92099
26. Mulrane L, Gallagher WM and O'Connor DP. A novel mechanism of regulation of the anti-metastatic miR-31 by EMSY in breast cancer. Breast cancer research :BCR. 2014; 16:467
27. Arias-Romero LE, Saha S, Villamar-Cruz O, Yip SC, Ethier SP, Zhang ZY and Chernoff J. Activation of Src by protein tyrosine phosphatase 1B Is required for ErbB2 transformation of human breast epithelial cells. Cancer Res. 2009; 69:4582-4588
28. Chan G, Kalaitzidis D and Neel BG. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer metastasis reviews. 2008; 27:179-192
29. Bunda S, Burrell K, Heir P, Zeng L, Alamsahebpour A, Kano Y, Raught B, Zhang ZY, Zadeh G and Ohh M. Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. Nature communications. 2015; 6:8859
30. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R and Haqq C. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Molecular cancer. 2006; 5:24
31. Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G and Kerin MJ. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 2009; 11:R27
32. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S and Kim VN. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003; 425:415-419
33. Bailey ST, Westerling T and Brown M. Loss of estrogenregulated microRNA expression increases HER2 signaling and is prognostic of poor outcome in luminal breast cancer. Cancer Res. 2015; 75:436-445
34. Lee JA, Lee HY, Lee ES, Kim I and Bae JW. Prognostic Implications of MicroRNA-21 Overexpression in Invasive Ductal Carcinomas of the Breast. Journal of breast cancer. 2011; 14:269-275
35. Leivonen SK, Sahlberg KK, Makela R, Due EU, Kallioniemi O, Borresen-Dale AL and Perala M. Highthroughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Molecular oncology. 2014; 8:93-104
36. Wu H, Xiao Z, Zhang H, Wang K, Liu W and Hao Q. MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3. Anticancer Drugs. 2014; 25:799-809
37. Mohi MG and Neel BG. The role of Shp2 (PTPN11) in cancer. Current opinion in genetics & development. 2007; 17:23-30
38. Matozaki T, Murata Y, Saito Y, Okazawa H and Ohnishi H. Protein tyrosine phosphatase SHP-2:a proto-oncogene product that promotes Ras activation. Cancer science. 2009; 100:1786-1793
39. Fang X, Yoon J-G, Li L, Yu W, Shao J, Hua D, Zheng S, Hood L, Goodlett D, Foltz G and Lin B. The SOX2 response program in glioblastoma multiforme:an integrated ChIP-seq, expression microarray, and microRNA analysis. BMC genomics. 2011; 12:11
40. Johnston RJ, Chang S, Etchberger JF, Ortiz CO and Hobert O. MicroRNAs acting in a double-negative feedback loop to control a neuronal cell fate decision. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102:12449-12454
41. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF and Goodall GJ. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008; 68:7846-7854
42. Yang X, Lin X, Zhong X, Kaur S, Li N, Liang S, Lassus H, Wang L, Katsaros D, Montone K, Zhao X, Zhang Y, Butzow R, Coukos G and Zhang L. Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res. 2010; 70:9463-9472
43. Filardo EJ, Quinn JA, Bland KI and A. Raymond Frackelton J. Estrogen-Induced Activation of Erk-1 and Erk-2 Requires the G Protein-Coupled Receptor Homolog, GPR30, and Occurs via Trans-Activation of the Epidermal Growth Factor Receptor through Release of HB-EGF. Molecular Endocrinology. 2000; 14:1649-1660
44. Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R and Colomer R. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer:Gefitinib (Iressa)-induced changes in the expression and nucleo-cytoplasmic trafficking of HERligands (Review). Int J Mol Med. 2007; 20:3-10
45. Santen RJ, Fan P, Zhang Z, Bao Y, Song RX and Yue W. Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and-resistant breast cancer cells. Steroids. 2008
46. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG and El-Ashry D. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Molecular endocrinology (Baltimore, Md). 2001; 15:1344-1359
47. Miller PC, Clarke J, Koru-Sengul T, Brinkman J and El-Ashry D. A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer. Clin Cancer Res. 2015; 21:373-385
48. Zhang SQ, Tsiaras WG, Araki T, Wen G, Minichiello L, Klein R and Neel BG. Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2. Mol Cell Biol. 2002; 22:4062-4072
49. Li SD, Chono S and Huang L. Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. Journal of controlled release :official journal of the Controlled Release Society. 2008; 126:77-84
50. Li SD and Huang L. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Molecular pharmaceutics. 2006; 3:579-588
51. Dvinge H, Git A, Graf S, Salmon-Divon M, Curtis C, Sottoriva A, Zhao Y, Hirst M, Armisen J, Miska EA, Chin SF, Provenzano E, Turashvili G, Green A, Ellis I, Aparicio S, et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature. 2013; 497:378-382
52. de Rinaldis E, Gazinska P, Mera A, Modrusan Z, Fedorowicz GM, Burford B, Gillett C, Marra P, Grigoriadis A, Dornan D, Holmberg L, Pinder S and Tutt A. Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. BMC genomics. 2013; 14:643
53. Chen H, Lee JS, Liang X, Zhang H, Zhu T, Zhang Z, Taylor ME, Zahnow C, Feigenbaum L, Rein A and Sukumar S. Hoxb7 inhibits transgenic HER-2/neu-induced mouse mammary tumor onset but promotes progression and lung metastasis. Cancer Res. 2008; 68:3637-3644
54. Chen H, Chung S and Sukumar S. HOXA5-induced apoptosis in breast cancer cells is mediated by caspases 2 and 8. Mol Cell Biol. 2004; 24:924-935
55. Liu S, Jin K, Hui Y, Fu J, Jie C, Feng S, Reisman D, Wang Q, Fan D, Sukumar S and Chen H. HOXB7 promotes malignant progression by activating the TGFbeta signaling pathway. Cancer Res. 2015; 75:709-719